{"bill": {"#text": " \n", "form": {"current-chamber": {"#tail": " \n", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": " \n", "congress": {"#tail": "\n", "#text": "113th CONGRESS"}, "#tail": " \n", "legis-num": {"#tail": " \n", "#text": "H. R. 672"}, "official-title": {"#tail": " \n", "#text": "To provide for increased Federal oversight of prescription opioid treatment and assistance to States in reducing opioid abuse, diversion, and deaths."}, "session": {"#tail": "\n", "#text": "1st Session"}, "distribution-code": {"#tail": " \n", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": " \n", "@date": "20130213", "#text": "February 13, 2013"}, "#tail": " \n", "action-desc": {"#tail": "\n", "#text": "\n        ", "sponsor": {"#tail": " introduced the following bill; which was referred to the ", "#text": "Mr. Rahall", "@name-id": "R000011"}, "committee-name": [{"#tail": ", and in addition to the Committee on the ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}, {"#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HJU00", "#text": "Judiciary"}]}, "#text": " \n"}, "legis-type": {"#tail": " \n", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H464EF83A66194FD48EF4514984DAA581", "@public-private": "public", "legis-body": {"#tail": " \n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "#text": "Prescription Drug Abuse Prevention and Treatment Act of 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H4E1527344F2B405F919B148D51D8C696"}, {"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " makes the following findings:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "\n        ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the proportion of all substance abuse treatment admissions aged 12 or older that reported any pain reliever abuse increased more than 400 percent between 1998 and 2008, from 2.2 to 9.8 percent.", "@entity-type": "federal-body", "#text": "Substance Abuse and Mental Health Services Administration", "@entity-id": "7522"}, "#text": "Nonmedical use of prescription pain relievers is a matter of increasing public health concern. According to the "}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H6D9983CEB62C4763BD8C3707680A9B9E", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "In 2008, among the population of the United States aged 12 or older, nonmedical use of prescription pain relievers was the second most prevalent type of illicit drug use, after marijuana use."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "HC5B038E297AB4B8A93E0B23DC676CD7F", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "When used properly under medical supervision, prescription opiates enable individuals with chronic pain to lead productive lives. However, when taken without a physician\u2019s oversight and direction, opiates can cause serious adverse health effects, resulting in dependence, abuse, and death."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "H283D4FFF712B42E691EF10428992C4CC", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "As with any controlled substance, there is a risk of abuse of methadone and other opiates."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "H6DCE29B0F1CD465CBF5FF7B84B2CCBA5", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "Methadone is an extensively tested, federally approved, and widely accepted method of treating addiction to prescription pain relievers or opiates."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "HB7AA35A72829423B8A84781AA13492A1", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "For more than 30 years, this synthetic prescription drug has been used for pain management and treatment for addiction to heroin, morphine, and other opioid drugs."}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "@id": "H787F97CA96C94C97B7B7F4B296CA05A4", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "The efficacy and lower cost of methadone has resulted in its being prescribed for pain management."}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "HB9AF05B6E201443F8D8059A4C8D455E2", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "Prescriptions for methadone have increased by nearly 700 percent from 1998 through 2006."}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "H9A8B9A88BDDE4F8CB7B9BC80EE76E7DF", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the number of poisoning deaths involving methadone increased nearly 7-fold from almost 790 in 1999 to almost 5,420 in 2006, which is the most rapid increase among opioid analgesics and other narcotics involved in poisoning deaths.", "@entity-type": "federal-body", "#text": "Centers for Disease Control and Prevention", "@entity-id": "7523"}, "#text": "According to the "}, "enum": {"#tail": "\n        ", "#text": "(9)"}, "@id": "H950B608AA7AF451BB498DFB40E9123DF", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "The age-specific rates of methadone death are higher for persons age 35 to 44 and 45 to 54 than for other age groups. However, the rate of methadone deaths in younger individuals (age 15 to 24) increased 11-fold from 1999 through 2005."}, "enum": {"#tail": "\n        ", "#text": "(10)"}, "@id": "H66660A97FFC649ACAB9218AF1350BF2B", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "Deaths from methadone and other opiates may actually be underreported. There is no comprehensive database of drug-related deaths in the United States."}, "enum": {"#tail": "\n        ", "#text": "(11)"}, "@id": "HB53A057C084F47ADA516B53A889620C1", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "quote": {"#tail": " on death certificates.", "#text": "cause of death"}, "#text": "The lack of standardized reporting by Medical Examiners precludes a uniform definition of "}, "enum": {"#tail": "\n        ", "#text": "(12)"}, "@id": "H20EBE206BE864B3A9BCF0D55C8ABAD02", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ". Unfortunately there is no requirement as a condition of receiving the registration that these practitioners receive any education on the use of these controlled narcotics, including methadone.", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}, "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " requires that every person who dispenses or who proposes to dispense controlled narcotics, including methadone, whether for pain management or opioid treatment obtain a registration from ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Controlled Substances Act", "@value": "Controlled Substances Act"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 801 et seq.", "@value": "usc/21/801/etseq"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(13)"}, "@id": "H3B6AAAEF44914A8EB110A5610441E28D", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n      ", "#text": "Current Federal oversight of methadone and other opioids is inadequate to address the growing number of opioid-related overdoses and deaths."}, "enum": {"#tail": "\n        ", "#text": "(14)"}, "@id": "H8D4E29CDC6784C1FBDF0D6EFA7D97F44", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "Federal legislation is needed to avert opioid abuse, misuse, and death, without reducing patient access to needed care."}, "enum": {"#tail": "\n        ", "#text": "(15)"}, "@id": "HF70EF61146EE4D78B79CD9877305CFA6", "#text": "\n        "}], "#text": "\n      ", "@id": "HF28F456491894576A4E72782EFE0E048"}, {"#tail": "\n", "text": {"#tail": "\n", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Part A of title V of the Public Health Service Act", "@value": "Public Health Service Act/t:V/pt:A"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 290aa et seq.", "@value": "usc/42/290aa/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Consumer education campaign"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "506C."}, "header": {"#tail": "\n", "#text": "Consumer education campaign"}, "subsection": [{"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall award grants to States and nonprofit entities for the purpose of conducting culturally sensitive consumer education about opioid abuse, including methadone abuse. Such education shall include information on the dangers of opioid abuse, how to prevent opioid abuse including through safe disposal of prescription medications and other safety precautions, and detection of early warning signs of addiction.", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "HCB9D2856BC794361BA464A4EFE9EDB86"}, {"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", an entity shall\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Public Health Service Act/s:506C/ss:a", "@proposed": "true"}, "#text": "To be eligible to receive a grant under "}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Eligibility"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n            ", "#text": "be a State or nonprofit entity; and"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "H45D66515879041FDADB0CAABA6FB5BEA", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " an application at such time, in such manner, and containing such information as the ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, {"#tail": " may require.", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}], "#text": "submit to the "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "HCEF80A2FF72245A8AD3AEB3598338083", "#text": "\n              "}], "#text": "\n            ", "@id": "HEBF36F6D24F7412F83C89EC3E29BD1A9"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall give priority to applicants that are States or communities with a high incidence of abuse of methadone and other opioids, and opioid-related deaths.", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, "#text": "In awarding grants under this section, the "}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Priority"}, "#text": "\n            ", "@id": "H9CCDBB5ECF4A4642B6F51A98C3C1F2B2"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall develop a process to evaluate the effectiveness of activities carried out by grantees under this section at reducing abuse of methadone and other opioids.", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n            ", "#text": "Evaluations"}, "#text": "\n            ", "@id": "HE6F3B047F42341D69BDD2FB2CB8272F1"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": "\n              ", "#text": "$15,000,000 for each of fiscal years 2014 through 2018", "@amount": "15000000", "@year": "2014, 2015, 2016, 2017, 2018"}, "@entity-type": "auth-auth-approp", "#text": "There is authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "act", "#text": "this section", "@value": "Public Health Service Act/s:506C", "@proposed": "true"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n            ", "#text": "(e)"}, "header": {"#tail": "\n            ", "#text": "Authorization of appropriations"}, "#text": "\n            ", "@id": "H05C2895AB77D4C43B881C72525896092"}], "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "H3619D3E4B5E54C0E8139F75163EA64BA", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "HEFD928A453C0405193EFE99878FFEA44"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "H603B021F393841B496AC8F498FC014DD", "@commented": "no"}, {"#tail": "\n", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n", "#text": "Practitioner education"}, "subsection": [{"#tail": "\n", "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n", "#text": "Education requirements"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "paragraph (5)", "@value": "Controlled Substances Act/s:303/ss:f/p:5"}, "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by inserting after ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 303(f) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303/ss:f"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 823(f)", "@value": "usc/21/823/f"}], "@entity-type": "law-citation", "#text": "\n              "}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Registration consideration"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "paragraph": {"#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " during any previous period in which the applicant has been subject to such training requirements.", "@entity-type": "act", "#text": "subsection (g)(3)", "@value": "Controlled Substances Act/s:303/ss:g/p:3", "@proposed": "true"}, "#text": "The applicant's compliance with the training requirements described in "}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "@id": "H895530DE96504445B4F7DDF474EF636F", "#text": "\n              "}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H0ADA78EBD4D24FA1911B988BDB354535"}, "#text": "\n          ", "@id": "HD3CACB1C74A44954AE1A347801C4649F"}, {"#tail": "\n      ", "text": {"#tail": "\n", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 303(g) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303/ss:g"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 823(g)", "@value": "usc/21/823/g"}], "@entity-type": "law-citation", "#text": "\n              "}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Training requirements"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "paragraph": {"@indent": "up1", "#tail": "\n            ", "@id": "H1CEF6B1F089F4AC3B0BDC0AEB5642B3F", "enum": {"#tail": "\n", "#text": "(3)"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall comply with the 16-hour training requirement of ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:303/ss:g/p:1"}, {"#tail": " at least once during each 3-year period.", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Controlled Substances Act/s:303/ss:g/p:3/sp:B", "@proposed": "true"}], "#text": "To be registered to prescribe or otherwise dispense methadone or other opioids, a practitioner described in "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "H90DD5B61156D4A87A96663D37BE66241", "@commented": "no"}, {"@indent": "up1", "continuation-text": {"#tail": "\n              ", "@continuation-text-level": "subparagraph", "#text": "that is provided by the American Society of Addiction Medicine, the American Academy of Addiction Psychiatry, the American Medical Association, the American Osteopathic Association, the American Psychiatric Association, the American Academy of Pain Management, the American Pain Society, the American Academy of Pain Medicine, the American Board of Pain Medicine, the American Society of Interventional Pain Physicians, or any other organization that the Secretary determines is appropriate for purposes of this subparagraph.", "@indent": "subsection"}, "#tail": "\n            ", "text": {"#tail": "\n", "#text": "The training requirement of this subparagraph is that the practitioner has completed not less than 16 hours of training (through classroom situations, seminars at professional society meetings, electronic communications, or otherwise) with respect to\u2014"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "clause": [{"#tail": "\n", "text": {"#tail": "\n                ", "#text": "the treatment and management of opioid-dependent patients;"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "H9627AA310B3545ADBE1821A004D29188", "@commented": "no"}, {"#tail": "\n", "text": {"#tail": "\n                ", "#text": "pain management treatment guidelines; and"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "H6C9F7BE14E23418BB53D6A97AA01FBB7", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n                ", "#text": "early detection of opioid addiction, including through such methods as Screening, Brief Intervention, and Referral to Treatment (SBIRT),"}, "enum": {"#tail": "\n                  ", "#text": "(iii)"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "HE2A484A607884BC2BF5E48B8CFF4CC0F", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "HD53999B1A1114B9AB1848787B450E260", "@commented": "no"}]}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "HBAC18B86A1D64D03A8E66C82B23C086E"}, "#text": "\n          ", "@id": "H93B5404D1A674F978A847F8D192C51DF"}], "#text": "\n        ", "@id": "H19ECF26A575D468CB6A5A5F31DECAB64"}, {"#tail": "\n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (as added by ", "@entity-type": "act", "#text": "section 303(g)(3) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303/ss:g/p:3", "@proposed": "true"}, {"#tail": ") with respect to required minimum training at least once during each 3-year period.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:4/ss:a", "@proposed": "true"}], "#text": "Effective July 1, 2014, a physician practicing in an opioid treatment program shall comply with the requirements of "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Requirements for participation in opioid treatment programs"}, "#text": "\n        ", "@id": "H376466BE05B345C39C46A5CA1D54A0C4"}, {"#tail": "\n", "text": {"#tail": "\n      ", "term": {"#tail": " has the meaning given such term in section 8.2 of title 42, Code of Federal Regulations (or any successor regulation).", "#text": "opioid treatment program"}, "#text": "In this section, the term "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Definition"}, "#text": "\n        ", "@id": "H09F0ADC35CBD4110AA2A0537F2E91447"}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall fund the enforcement of the requirements specified in ", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}, {"#tail": " (as added by ", "@entity-type": "act", "#text": "section 303(g)(3) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303/ss:g/p:3", "@proposed": "true"}, {"#tail": ") through the use of a portion of the licensing fees paid by controlled substance prescribers under the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:4/ss:a", "@proposed": "true"}], "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Controlled Substances Act", "@value": "Controlled Substances Act"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 801 et seq.", "@value": "usc/21/801/etseq"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Funding"}, "#text": "\n        ", "@id": "H602C9068EF50427BB61842907AFC02BD"}], "#text": "\n      ", "@id": "HDA8D9CE9234E4BE08730BE51FDC8FB0F"}, {"#tail": "\n", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n", "#text": "Moratorium on methadone hydrochloride tablets"}, "subsection": [{"#tail": "\n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", no individual or entity may prescribe or otherwise dispense a 40-mg diskette of methadone unless such prescription or dispensation is consistent with the methadone 40-mg diskette policy of the ", "@entity-type": "act", "#text": "subsection (b)", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:5/ss:b", "@proposed": "true"}, {"#tail": " as in effect on the date of enactment of this Act, except that such prohibition shall extend to hospitals unless such hospitals provide for direct patient supervision with respect to such methadone.", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}], "#text": "Notwithstanding any other provision of law, during the period beginning on the date of enactment of this Act and ending on the date described in "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "#text": "\n        ", "@id": "H767EF023EFB349F3B2C14C1C52829E02", "@commented": "no"}, {"#tail": "\n    ", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall cease to have force and effect\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:5/ss:a", "@proposed": "true"}, "#text": "The moratorium under "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Ending date of moratorium"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " publishes in the Federal Register dosing guidelines for all forms of methadone, in accordance with ", "@entity-type": "federal-body", "#text": "Controlled Substances Clinical Standards Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " (as added by ", "@entity-type": "act", "#text": "section 506D(b)(1)(A) of the Public Health Service Act", "@value": "Public Health Service Act/s:506D/ss:b/p:1/sp:A", "@proposed": "true"}, {"#tail": "); and", "@entity-type": "act", "#text": "section 7", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:7", "@proposed": "true"}], "#text": "on the date that the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "H605CD477C5C640BB8419761B138ACA21", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " finds that 40-mg diskettes of methadone are safe and clinically appropriate.", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, "#text": "if, as part of such dosing guidelines, such "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "#text": "\n          ", "@id": "HA1653647816E452A9BF7C67622592506", "@commented": "no"}], "#text": "\n        ", "@id": "HABA02F17102B4ADFB5485EE2707E37B3", "@commented": "no"}], "#text": "\n      ", "@id": "H34DB664AB0D640E79E540CE3A8C521DF", "@commented": "no"}, {"#tail": "\n", "text": {"#tail": "\n", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 303 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 823", "@value": "usc/21/823"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n      ", "#text": "Operation of opioid treatment programs"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "subsection": {"#tail": "\n        ", "#text": "\n          ", "enum": {"#tail": "\n", "#text": "(i)"}, "@id": "HF5BFA8E096B743B6B44302E591E6369B", "paragraph": [{"#tail": "\n", "text": {"#tail": "\n          ", "#text": "An opioid treatment program that is registered under this section, and that closes for business on any weekday or weekend day, including a Federal or State holiday, shall comply with the requirements of this subsection."}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@display-inline": "yes-display-inline", "#text": "\n            ", "@id": "H5C8B2A2CC31A418BAA3332AFE980D9A5", "@commented": "no"}, {"@indent": "up1", "#tail": "\n", "text": {"#tail": "\n          ", "#text": "The program shall make acceptable arrangements for each patient who is restricted, by Federal regulation or guideline or by the determination of the program medical director, from having a take home dose of a controlled substance related to the treatment involved, to receive a dose of that substance under appropriate supervision during the closure."}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "#text": "\n            ", "@id": "HA20CF3E3A1F34992BB75B88000839E8C"}, {"@indent": "up1", "#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall issue a notice that references regulations on acceptable arrangements under this subsection, or shall promulgate regulations on such acceptable arrangements.", "@entity-type": "federal-body", "#text": "Administrator of the Substance Abuse and Mental Health Services Administration", "@entity-id": "7522"}, "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "#text": "\n            ", "@id": "HC7D8B0EA3DD34DC7BADFE01A6F9A9195"}]}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "HC708F833B2D347D28C33E698420AF4BC"}, "#text": "\n      ", "@id": "HF4AD35CCAB5A4FA09559C4CBDE468CC6"}, {"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", is further amended by adding at the end the following:", "@entity-type": "act", "#text": "section 3", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:3", "@proposed": "true"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", as amended by ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Part A of title V of the Public Health Service Act", "@value": "Public Health Service Act/t:V/pt:A"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 290aa et seq.", "@value": "usc/42/290aa/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "7."}, "header": {"#tail": "\n      ", "#text": "Establishment of the Controlled Substances Clinical Standards Commission"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "506D."}, "header": {"#tail": "\n", "#text": "Establishment of the Controlled Substances Clinical Standards Commission"}, "subsection": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish a ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " (referred to in this section as the ", "@entity-type": "federal-body", "#text": "Controlled Substances Clinical Standards Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Administration", "@entity-id": "7522"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Centers for Disease Control and Prevention", "@entity-id": "7523"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, {"#tail": ", and other agencies that the ", "@entity-parent-id": "7529", "@entity-type": "federal-body", "#text": "Pain Management Consortia of the National Institutes of Health", "@value": "Pain Management Consortia"}, {"#tail": " may deem necessary, to develop\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "term": {"#tail": "), to be composed of representatives from the ", "#text": "Commission"}, "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "subsection (b)(1)", "@value": "Public Health Service Act/s:506D/ss:b/p:1", "@proposed": "true"}, "#text": "appropriate and safe dosing guidelines for all forms of methadone, including recommendations for maximum daily doses of all forms as provided for in "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "H3A0D867BB7764ED18C729E3E91BA3B4A", "#text": "\n              "}, {"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "subsection (b)(2)", "@value": "Public Health Service Act/s:506D/ss:b/p:2", "@proposed": "true"}, "#text": "benchmark guidelines for the reduction of methadone abuse, as provided for in "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "H4B85C21B8E30410785181676570522F4", "#text": "\n              "}, {"#tail": "\n", "text": {"#tail": "\n            ", "#text": "appropriate conversion factors for use by health care providers in transitioning patients from one opioid to another;"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "@id": "HCC0B8225C7E94DAE9B63715BAAB3BB45", "#text": "\n              "}, {"#tail": "\n", "text": {"#tail": "\n            ", "#text": "specific guidelines for initiating pain management with methadone that prescribing practitioners shall comply with in order to meet certification requirements set forth in ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "part C of the Controlled Substances Act", "@value": "Controlled Substances Act/pt:C"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 821 et seq.", "@value": "usc/21/821/etseq"}], "@entity-type": "law-citation", "#text": "\n                  "}}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "@id": "HE6776FDCDDF34F2283F378D902AB1BE3", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "patient and practitioner education guidelines for both methadone maintenance therapy and pain management that apply to safe and effective use and include detoxification."}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "@id": "HD96268CA1905406CA596B840AEB11C9F", "#text": "\n              "}], "#text": "\n            ", "@id": "H699FC45E52C74CCCA0067536308E0AC9"}, {"#tail": "\n", "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n", "#text": "Guidelines"}, "paragraph": [{"#tail": "\n", "subparagraph": [{"#tail": "\n", "clause": [{"#tail": "\n", "text": {"#tail": "\n                ", "#text": "safe and clinically appropriate dosing guidelines for all forms of methadone used for both pain management and opioid treatment programs, including recommendations for maximum daily doses of all forms, including recommendations for the induction process for patients who are newly prescribed methadone;"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H103B4BC9FA6244CCB750533B64F5B16C", "#text": "\n                  "}, {"#tail": "\n", "text": {"#tail": "\n                ", "#text": "requirements for individual patient care plans, including initial and follow-up patient physical examination guidelines, and recommendations for screening patients for chronic or acute medical conditions that may cause an immediate and adverse reaction to methadone;"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H2BC7B46A73A74DF7AEEDA5958CA5EE44", "#text": "\n                  "}, {"#tail": "\n", "text": {"#tail": "\n                ", "#text": "appropriate conversion factors for use by health care providers in transitioning patients from one opioid to another;"}, "enum": {"#tail": "\n                  ", "#text": "(iii)"}, "@id": "H0FE265B197974F0398CD77607E38AE86", "#text": "\n                  "}, {"#tail": "\n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " certification and re-certification requirements; and", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}, "#text": "specific guidelines for initiating pain management with methadone, that prescribing physicians or other clinicians shall comply with in order to meet "}, "enum": {"#tail": "\n                  ", "#text": "(iv)"}, "@id": "H0E51ED3E5E424D6E9AEADA5DB92B239A", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "consensus guidelines for pain management with prescription opioid drugs."}, "enum": {"#tail": "\n                  ", "#text": "(v)"}, "@id": "HF419C720E9084F089134041AF31ACFEE", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In general"}, "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " established under ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " shall publish in the Federal Register\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Public Health Service Act/s:506D/ss:a", "@proposed": "true"}], "#text": "Not later than 2 years after the date of enactment of this section, the "}, "#text": "\n                ", "@id": "H7CEF3AAE2FBD4A8C9E5831ECC1312B18"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", and at least every 3 years thereafter, the ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Public Health Service Act/s:506D/ss:b/p:1/sp:A", "@proposed": "true"}, {"#tail": " shall update such guidelines.", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}], "#text": "Not later than 3 years after the publication of guidelines under "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Updating of guidelines"}, "#text": "\n                ", "@id": "H65FC07A5D87D4A39837D1D5A8CD4D436"}], "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n", "#text": "Publication of dosing guidelines"}, "#text": "\n              ", "@id": "H7A5EA35490B84CA0815ABF68D39AB4D7"}, {"#tail": "\n", "subparagraph": [{"#tail": "\n", "clause": [{"#tail": "\n", "text": {"#tail": "\n", "#text": "the initial benchmark guidelines for the reduction of methadone abuse to be used\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "subclause": [{"#tail": "\n", "text": {"#tail": "\n                  ", "#text": "by opioid treatment programs in providing methadone therapy; and"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "HB7F98AA94A414F399DF4BBBA8437A13A", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "by entities in the initial accreditation or certification, and the re-accreditation and re-certification, of such opioid treatment programs;"}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "H3635FD045E3C48D584D3D4DF3F1F45D3", "#text": "\n                    "}], "#text": "\n                  ", "@id": "HC13ECC62E4144C6E9E41B7A8312CB662"}, {"#tail": "\n", "text": {"#tail": "\n                ", "#text": "a model policy for dispensing methadone to be used by pharmacists that dispense methadone, which should include education and training guidelines for such pharmacists;"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H125535DE9728492A81D8841AFCF8B48A", "#text": "\n                  "}, {"#tail": "\n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " certification and re-certification requirements, as set forth in ", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}, "#text": "the continuing education guidelines that all prescribers shall comply with in order to meet ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", which should include a minimum of 16 training hours at least every 3 years that include the integration of both addiction and pain management curricula; and", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 303(g)(3) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303/ss:g/p:3"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 823(g)(3)", "@value": "usc/21/823/g/3"}], "@entity-type": "law-citation", "#text": "\n                      "}}, "enum": {"#tail": "\n                  ", "#text": "(iii)"}, "@id": "H078F858A1D2F455F831C36028B900514", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "patient education guidelines for both opioid treatment programs and pain management, including recommendations for patient counseling prior to and during opioid addiction treatment or treatment for pain."}, "enum": {"#tail": "\n                  ", "#text": "(iv)"}, "@id": "HBAB46A8733A54B51A5DB2715163DEA15", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In general"}, "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " established under ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " shall publish in the Federal Register\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Public Health Service Act/s:506D/ss:a", "@proposed": "true"}], "#text": "Not later than 3 years after the date of enactment of this section, the "}, "#text": "\n                ", "@id": "H4C156E1C7E6647DD8A4208CB4AADF354"}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", and at least annually thereafter, the ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Public Health Service Act/s:506D/ss:b/p:2/sp:A", "@proposed": "true"}, {"#tail": " shall update the guidelines published under ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " and ", "@entity-type": "act", "#text": "clauses (iii)", "@value": "Public Health Service Act/s:506D/ss:b/p:2/sp:A/cl:iii", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "(iv) of such subparagraph", "@value": "Public Health Service Act/s:506D/ss:b/p:2/sp:A/cl:iv", "@proposed": "true"}], "#text": "Not later than 1 year after the publication of guidelines under "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Updating of guidelines"}, "#text": "\n                ", "@id": "HDE475AA58B92497B8EACECC43CFD5E88"}], "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n", "#text": "Publication of benchmark guidelines"}, "#text": "\n              ", "@id": "HD966277CA6F84A429E98398DA4D7FD38"}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall consult with relevant professional organizations with expertise in the area of addiction, relevant professional organizations with expertise in the area of pain management, physician groups, pharmacy groups (including the National Association of Boards of Pharmacy), patient representatives, and any other organization that the ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " determines is appropriate for purposes of this section.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In developing and publishing the guidelines under this section, the "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Consultation"}, "#text": "\n              ", "@id": "H2CEB609E4AC34669B0D86C47D90B25C8"}], "#text": "\n            ", "@id": "H07AD05951E5B455394077C746EA0C69D"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish and operate a ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " website.", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}], "#text": "Not later than 180 days after the date of enactment of this section, the "}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Website"}, "#text": "\n            ", "@id": "H2C538A7472E34BF6AB2AB015E36FCE53"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish, and distribute to practitioners that are registered to prescribe or otherwise dispense methadone, a methadone toolkit. The ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " shall make the components of the toolkit that are available in electronic form available on the ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": " website.", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}], "#text": "Not later than 1 year after the date of enactment of this section, the "}, "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n            ", "#text": "Methadone toolkit"}, "#text": "\n            ", "@id": "HD30DC1AD6EE14330B024384F32EA5BFA"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall develop a practitioner education program that shall be used for the practitioner education described in ", "@entity-type": "federal-body", "#text": "Commission", "@value": "Controlled Substances Clinical Standards Commission", "@proposed": "true"}, {"#tail": ", and shall make such program available to providers of such practitioner education.", "@entity-type": "act", "#text": "section 303(g)(3) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:303/ss:g/p:3", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(e)"}, "header": {"#tail": "\n            ", "#text": "Practitioner education program"}, "#text": "\n            ", "@id": "HADD88AD0CC9E466D9192328C38AD700A"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ".", "#text": "such sums as may be necessary for each of fiscal years 2014 through 2018", "@amount": "indefinite", "@year": "2014, 2015, 2016, 2017, 2018"}, "@entity-type": "auth-auth-approp", "#text": "There is authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "act", "#text": "this section", "@value": "Public Health Service Act/s:506D", "@proposed": "true"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n            ", "#text": "(f)"}, "header": {"#tail": "\n            ", "#text": "Authorization of appropriations"}, "#text": "\n            ", "@id": "HB40AA8C2F99048BB9BB23D64E2CE1DBA"}], "#text": "\n          ", "@id": "HA0B7223B5DB34A29B9525343F45EFA83"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H2FF5306C4DEF4485BB3D4E4FE0DB316B"}, "#text": "\n      ", "@id": "H9D88F67D36D6412CB43817527C9B8883"}, {"#tail": "\n", "text": {"#tail": "\n", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Section 399O of the Public Health Service Act", "@value": "Public Health Service Act/s:399O"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 280g\u20133", "@value": "usc/42/280g\u20133"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "8."}, "header": {"#tail": "\n      ", "#text": "Prescription monitoring program"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by inserting ", "@entity-type": "act", "#text": "subsection (d)(1)", "@value": "Public Health Service Act/s:399O/ss:d/p:1"}, "#text": "in ", "quote": [{"#tail": " after ", "#text": "(including prescribers of methadone)"}, {"#tail": ";", "#text": "dispensers"}]}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "HA9BA13782C9E45E98EE148F7F9865FA5", "#text": "\n        "}, {"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by adding at the end the following:", "@entity-type": "act", "#text": "subsection (e)", "@value": "Public Health Service Act/s:399O/ss:e"}, "#text": "in "}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "; and"}, "#tail": "\n      ", "paragraph": {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the State shall, at the request of a Federal, State, or local officer whose duties include enforcing laws relating to drugs, provide to such officer information from the database relating to an individual who is the subject of an active drug-related investigation conducted by the officer's employing government entity.", "@entity-type": "act", "#text": "section 543", "@value": "Public Health Service Act/s:543"}, "#text": "Subject to the requirements of "}, "enum": {"#tail": "\n            ", "#text": "(5)"}, "@id": "H66801952908340518844C22F47C3F53A", "#text": "\n            "}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H62BC7C704F614D0986AD47924714A695"}, "#text": "\n        ", "@id": "HD215CBA9B5F049A097B6C5B9C9C9AA86"}, {"#tail": "\n    ", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " and inserting the following:", "@entity-type": "act", "#text": "subsection (n)", "@value": "Public Health Service Act/s:399O/ss:n"}, "#text": "by striking ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": ". "}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "text": {"#tail": "\n          ", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ".", "#text": "$25,000,000 for each of fiscal years 2014 through 2018", "@amount": "25000000", "@year": "2014, 2015, 2016, 2017, 2018"}, "@entity-type": "auth-auth-approp", "#text": "There is authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "act", "#text": "this section", "@value": "Public Health Service Act/s:399O"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n            ", "#text": "(n)"}, "header": {"#tail": "\n            ", "#text": "Appropriations"}, "#text": "\n            ", "@id": "H4D7BF118D25E471A9DFEFBCB648700CD"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H2E9A54692A44475F83BA793C716A392C"}, "#text": "\n        ", "@id": "H1B375A6F678B4731A13A03958ED2199C"}], "#text": "\n      ", "@id": "H3921D562B439432A896BA1892319CC58"}, {"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", is further amended by adding at the end the following:", "@entity-type": "act", "#text": "section 7", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:7", "@proposed": "true"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", as amended by ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Part A of title V of the Public Health Service Act", "@value": "Public Health Service Act/t:V/pt:A"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 290aa et seq.", "@value": "usc/42/290aa/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "9."}, "header": {"#tail": "\n      ", "#text": "Mortality reporting"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "506E."}, "header": {"#tail": "\n", "#text": "Mortality reporting"}, "subsection": [{"#tail": "\n", "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n", "#text": "Model Opioid Treatment Program Mortality Report"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", shall require that a Model Opioid Treatment Program Mortality Report be completed and submitted to the ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, {"#tail": " for each individual who dies while receiving treatment in an opioid treatment program.", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}], "#text": "Not later than July 1, 2014, the "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "#text": "\n              ", "@id": "HD3AB70D1A47D496C868B7C77782F114F"}, {"#tail": "\n", "@id": "H02F8C4DFBCF94098AB46A4C7BA11F733", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Requirement of States that receive funding for the Controlled Substance Monitoring Program"}, "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", each State shall require that any individual who signs a death certificate where an opioid drug is detected in the body of the deceased, or where such drug is otherwise associated with the death, report such death to the ", "@entity-type": "act", "#text": "section 399O", "@value": "Public Health Service Act/s:399O", "@proposed": "true"}, {"#tail": " by submitting a Model Opioid Treatment Program Mortality Report described in ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, {"#tail": ". Such report shall be submitted to the ", "@entity-type": "act", "#text": "paragraph (3)", "@value": "Public Health Service Act/s:506E/ss:a/p:3", "@proposed": "true"}, {"#tail": " on or before the later of\u2014", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}], "#text": "As a condition for receiving funds under "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n              ", "#text": "90 days after the date of signing the death certificate; or"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HD2A96373CF6E4D2B9808FA3B1AD9A444", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "as soon as practicable after the date on which the necessary postmortem and toxicology reports become available to such individual, as required by the "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H0AE1EAF3B10F45D9B20EDE63370E16E1", "#text": "\n                "}]}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", in consultation with State and local medical examiners, prescribing physicians, hospitals, and any other organization that the ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, {"#tail": " determines appropriate, shall develop a Model Opioid Treatment Program Mortality Report to be used under ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, {"#tail": " and ", "@entity-type": "act", "#text": "paragraphs (1)", "@value": "Public Health Service Act/s:506E/ss:a/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "(2)", "@value": "Public Health Service Act/s:506E/ss:a/p:2", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Development"}, "#text": "\n              ", "@id": "H76D2610736AC485E949FA238B2757482"}], "#text": "\n            ", "@id": "H5C90453410D74C3097A33BF4648A7FAF"}, {"#tail": "\n", "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n", "#text": "National Opioid Death Registry"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall establish and implement, through the National Center for Health Statistics, a National Opioid Death Registry (referred to in this subsection as the ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, "term": {"#tail": ") to track opioid-related deaths and information related to such deaths.", "#text": "Registry"}, "#text": "Not later than July 1, 2014, the "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "#text": "\n              ", "@id": "H8E09DF5154054EF1B082AE5B60660D25"}, {"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall consult with the Administrator, State and local medical examiners, prescribing physicians, hospitals, and any other organization that the ", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}, {"#tail": " determines is appropriate for purposes of this subsection.", "@entity-type": "federal-body", "#text": "Director", "@entity-id": "7523"}], "#text": "In establishing the uniform reporting criteria for the Registry, the "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Consultation"}, "#text": "\n              ", "@id": "H69A69F4EB25C405EA6770C486C10FB03"}, {"#tail": "\n", "@id": "H23BDE28B283B4EDDBF57010D0AA4547D", "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Requirements"}, "text": {"#tail": "\n", "#text": "The registry shall be designed as a uniform reporting system for opioid-related deaths and shall require the reporting of information with respect to such deaths, including\u2014"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n              ", "#text": "the particular drug formulation used at the time of death;"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H9E2FC2202FD24D529A852805C3596D0C", "#text": "\n                "}, {"#tail": "\n", "text": {"#tail": "\n              ", "#text": "the dosage level;"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H4DECFF0C729D48049FE8A157FA68D795", "#text": "\n                "}, {"#tail": "\n", "text": {"#tail": "\n              ", "#text": "a description of the circumstances surrounding the death in relation to the recommended dosage involved;"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "HB7CE2E6A384F446D8A1131F280DC8DE4", "#text": "\n                "}, {"#tail": "\n", "text": {"#tail": "\n              ", "#text": "a disclosure of whether the medication involved can be traced back to a physician\u2019s prescription;"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "H191CCC52A0484A44BF67F4917C97F9C0", "#text": "\n                "}, {"#tail": "\n", "text": {"#tail": "\n              ", "#text": "a disclosure of whether the individual was in an opioid treatment program at the time of death;"}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@id": "H9E72D7659D95476E95FAD1F104B43140", "#text": "\n                "}, {"#tail": "\n", "text": {"#tail": "\n              ", "#text": "the age and sex of the individual; and"}, "enum": {"#tail": "\n                ", "#text": "(F)"}, "@id": "H96D7357CACD24355AFF8DB99AA2711DF", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "other non-personal information such as that included in filed National Association of Medical Examiners Pediatric Toxicology Registry case reports as required under the privacy standard for the de-identification of health information pursuant to the regulations contained in part 164 of title 45, Code of Federal Regulations."}, "enum": {"#tail": "\n                ", "#text": "(G)"}, "@id": "H27552411D05345F899C8D8BAC19E5C02", "#text": "\n                "}]}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "#text": "\n                ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n              ", "@entity-type": "auth-auth-approp", "#text": "There is authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": " ", "#text": "$5,000,000 for each of fiscal years 2014 through 2018", "@amount": "5000000", "@year": "2014, 2015, 2016, 2017, 2018"}, "{http://namespaces.cato.org/catoxml}property": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "this subsection", "@value": "Public Health Service Act/s:506E/ss:b", "@proposed": "true"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n              ", "#text": "Authorization"}, "#text": "\n              ", "@id": "H41389833E60D4CF2831E9AD4D7470FC6"}], "#text": "\n            ", "@id": "H4E53BC85317A4FE19FCE0FD581D4CC58"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to the ", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}, {"#tail": " a report, based on information contained in the Registry described in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", concerning the number of methadone-related deaths in the United States for the year for which the report is submitted.", "@entity-type": "act", "#text": "subsection (b)", "@value": "Public Health Service Act/s:506E/ss:b", "@proposed": "true"}], "#text": "Not later than the January 1 of the first fiscal year beginning 2 years after the date of enactment of this section, and each January 1 thereafter, the "}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Report on Registry information"}, "#text": "\n            ", "@id": "HE44B5F853FC846809D4271855F0A128F"}], "#text": "\n          ", "@id": "HBC0DFE8F87894249B5E444E614B7EBAB"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H3F2994DD7967416F97905E547F95F5B4"}, "#text": "\n      ", "@id": "HF3895EDC03B0447C91A28119510ED8B4"}, {"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", is further amended by adding at the end the following:", "@entity-type": "act", "#text": "section 9", "@value": "Prescription Drug Abuse Prevention and Treatment Act of 2013/s:9", "@proposed": "true"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", as amended by ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Part A of title V of the Public Health Service Act", "@value": "Public Health Service Act/t:V/pt:A"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 290aa et seq.", "@value": "usc/42/290aa/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "10."}, "header": {"#tail": "\n      ", "#text": "Additional reporting"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "506F."}, "header": {"#tail": "\n", "#text": "Additional reporting"}, "subsection": [{"#tail": "\n", "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n", "#text": "Report on methadone usage"}, "paragraph": [{"#tail": "\n", "@id": "HFC3FFC2CE9BB4E1D9CD1ACC4E9279DC0", "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-type": "federal-body", "#text": "Administrator", "@entity-id": "7522"}, {"#tail": " shall submit to the ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, {"#tail": " a report containing detailed statistics on methadone usage for opioid treatment and pain management. Such statistics shall include\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Not later than January 1 of the first fiscal year beginning 2 years after the date of enactment of this section, and each January 1 thereafter, the "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n              ", "#text": "information on the distribution of prescribed doses of methadone at federally qualified health centers, opioid treatment clinics, other health-related clinics, physician offices, pharmacies, and hospitals; and"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HCCB12B82539A41DBB005FC525B606C69", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "information relating to adverse health events resulting from such methadone usage."}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H2A00D1E5817D4E53986063A649D5F475", "#text": "\n                "}]}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall make the reports submitted under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " available to the general public, including through the use of the Internet website of the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Public Health Service Act/s:506F/ss:a/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Department of Health and Human Services", "@entity-id": "7500"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Availability of information"}, "#text": "\n              ", "@id": "HB4201C8D4F0F4FDDBE3430B49DAA5974"}], "#text": "\n            ", "@id": "H0C0721A66C3D43769BABA08DA2E94B75"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to the appropriate committees of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", a report concerning the effectiveness of the methadone maintenance therapy program. Such report shall evaluate the success of efforts to reduce opioid addiction and methadone-related deaths, including the impact of health care provider and patient education.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later than September 30, 2014, and annually thereafter until September 30, 2016, the "}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Annual report on effectiveness"}, "#text": "\n            ", "@id": "H27E0D8D7E5764C8E9541628763ACF3CC"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ".", "#text": "such sums as may be necessary for each of fiscal years 2014 through 2018", "@amount": "indefinite", "@year": "2014, 2015, 2016, 2017, 2018"}, "@entity-type": "auth-auth-approp", "#text": "There is authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": " ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "act", "#text": "this section", "@value": "Public Health Service Act/s:506F", "@proposed": "true"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Authorization of appropriations"}, "#text": "\n            ", "@id": "H3793BAC1F86640C9969E7D5CE7787302"}], "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "HC89497A1B7B446ABBCC130D9E1A093F8", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H0983A498E31E47B8969FFA89CA3C3236"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "H375EAF58DBF54C47B230BC7DCAFD0B00", "@commented": "no"}, {"#tail": " \n", "text": {"#tail": "\n", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Subpart I of part D of title IX of the Public Health Service Act", "@value": "Public Health Service Act/t:IX/pt:D/spt:I"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C. 299b-31 et seq.", "@value": "usc/42/299b-31/etseq"}], "@entity-type": "law-citation", "#text": "\n          "}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "11."}, "header": {"#tail": "\n      ", "#text": "Development of prescription drug abuse prevention and treatment quality measures across each relevant provider setting"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "932."}, "header": {"#tail": "\n", "#text": "Development of prescription drug abuse prevention and treatment quality measures across each relevant provider setting"}, "subsection": [{"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and in consultation with the ", "@entity-type": "federal-body", "#text": "Director of the Agency for Healthcare Research and Quality", "@entity-id": "7528"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and Prevention", "@entity-id": "7523"}, {"#tail": ", and the ", "@entity-type": "federal-body", "#text": "Administrator of the Substance Abuse and Mental Health Services Administration", "@entity-id": "7522"}, {"#tail": ", shall require the development and application of specific prescription drug abuse prevention and treatment quality measures for each relevant health care provider setting, as identified by the Director.", "@entity-type": "federal-body", "#text": "Director of the Centers for Medicare & Medicaid Services", "@entity-id": "7530"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "In general"}, "#text": "\n            ", "@id": "HAA18F1B57FC94C0DBD0178BDEF8949A4"}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall disseminate the quality measure requirements developed under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " to all affected providers.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Public Health Service Act/s:932/ss:a", "@proposed": "true"}], "#text": "Not later than April 1, 2016, the "}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Dissemination"}, "#text": "\n            ", "@id": "H528B247071ED4E769775BFD7365C26C1"}, {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "Quality measures developed under this section may be structure-oriented (such as the required presence of a hospital-based treatment program), process-oriented (such as requiring patients to be informed of the addictive qualities of the medication being prescribed), or outcome-oriented (such as assessing family satisfaction with care)."}, "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n            ", "#text": "Types of measures"}, "#text": "\n            ", "@id": "H38D7EE4D338E43DD8A502A11BEF9C212"}], "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "H3ADC6F9108EB4B3F8382EA860A6AB5E4", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H443C54AC343D49F69FA86026B0255839"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "HADB90D9EBDA6404899F0E3CF51DB2F97", "@commented": "no"}], "#text": " \n", "@id": "H2CCF75307F03462EB1EEB8F48D96BDFD"}}}